Acumen Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ABOS Nasdaq 2836 acumenpharm.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Inc (ABOS) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... - May 14th, 2025 1:06 am
Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights - May 13th, 2025 5:00 am
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference - May 7th, 2025 2:00 pm
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 - May 6th, 2025 2:00 pm
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting - Apr 2nd, 2025 5:00 am
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors - Apr 1st, 2025 5:00 am
Acumen Pharmaceuticals Inc (ABOS) Q4 2024 Earnings Call Highlights: Strong Financial Position ... - Mar 28th, 2025 1:01 am
Acumen concludes enrolment in Phase II trial of sabirnetug for Alzheimer’s - Mar 27th, 2025 6:22 am
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights - Mar 27th, 2025 5:00 am
Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease - Mar 26th, 2025 6:00 am
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 - Mar 20th, 2025 2:00 pm
Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers - Mar 19th, 2025 6:00 am
Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer’s - Mar 18th, 2025 6:48 am
Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting - Mar 12th, 2025 6:00 am
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - Mar 10th, 2025 2:00 pm
Promising US Penny Stocks To Consider In January 2025 - Jan 24th, 2025 1:10 pm
Acumen announces Phase 1 INTERCEPT-AD study publication - Jan 10th, 2025 6:05 am
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings - Jan 9th, 2025 6:00 am
I-Mab Leads Our Spotlight On 3 US Penny Stocks - Dec 4th, 2024 6:04 am
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference - Nov 26th, 2024 2:00 pm